ImmuCell

ImmuCell Intangible Assets

The Intangible Assets of ImmuCell (ICCC) as of Oct 8, 2026 is 19,100.00 USD. In the previous year, Intangible Assets was 38,200.00 USD — a change of -50.00% (lower).

Intangible Assets

19,100.00USD

YoY

-50.00%

Last updated:

Intangible Assets of ImmuCell is 2024 19,100.00 USD. Intangible Assets of ImmuCell was 2023 38,200.00 USD. It decreases by -50.00% lower compared to the previous year.

The ImmuCell Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
150,000.00 USD
Jan 1, 2018
130,000.00 USD
Jan 1, 2019
110,000.00 USD
Jan 1, 2020
100,000.00 USD
Jan 1, 2021
80,000.00 USD
Jan 1, 2022
60,000.00 USD
Jan 1, 2023
38,200.00 USD
Jan 1, 2024
19,100.00 USD
The ImmuCell Intangible Assets history
YEARIntangible AssetsYoY
19,100.00USD-50.00%
38,200.00USD-36.33%
60,000.00USD-25.00%
80,000.00USD-20.00%
100,000.00USD-9.09%
110,000.00USD-15.38%
130,000.00USD-13.33%
150,000.00USD-11.76%
170,000.00USD—
0.00USD—
Access this data via the Eulerpool API

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

Intangible Assets of ImmuCell is 19,100.00 USD in 2024.

Intangible Assets of ImmuCell changed from 38,200.00 USD to 19,100.00 USD, representing a -50.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets ImmuCell since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's ImmuCell historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — ImmuCell

All Key Metrics — ImmuCell